BTK and B-cell chronic lymphocytic leukemia: Consequently, drugs that block the action of BTK are highly effective and fundamentally have changed the standard of care for patients with CLL since the therapeutic introduction of the first BTK inhibitor (BTKi), ibrutinib, in 2013.